Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Ryan Haffey

Physical Medicine & Rehabilitation New York, NY Doctor of Osteopathy

NPI 1306209481 CMS profile 10145122

180 Fort Washington Ave Ste 199, Ste 199, New York, NY 10032

Open in the dashboard

General payments

$7,698

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Ryan Haffey of New York, NY is reported in the CMS Open Payments database as having received $7,698 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $370 6
2024 General $441 5
2023 General $1,240 14
2022 General $1,884 14
2021 General $3,666 10
2019 General $97 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Ryan Haffey
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Paul Ryan Haffey were reported at $370. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Paul Ryan Haffey Physical Medicine & Rehabilitation median Middle half National median
2019 $97 $133 $45–$390 $163
2020 $0 $88 $29–$272 $114
2021 $3,666 $116 $33–$360 $132
2022 $1,884 $123 $40–$378 $149
2023 $1,240 $131 $43–$396 $160
2024 $441 $141 $45–$409 $164
2025 $370 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,999 8 payments
  2. Stratus Medical, LLC $1,724 12 payments
  3. SPR Therapeutics, Inc $1,230 14 payments
  4. Nevro Corp. $686 9 payments
  5. Nalu Medical, Inc. $272 2 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $266 1 payment
  7. Vertos Medical, Inc. $232 1 payment
  8. Abbott Laboratories $138 1 payment
  9. MML US, Inc. $129 1 payment
  10. Amgen Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,193 48 payments
  2. Grant $2,500 1 payment
  3. Travel and Lodging $6 1 payment
Products named General payments · program years 2019–2025
  1. SYNCHROMED $2,500 1 payment
  2. Nimbus $1,724 12 payments
  3. SPRINT PNS System $1,230 14 payments
  4. Omnia $424 5 payments
  5. SYNCHROMEDII $307 4 payments
  6. Nalu Neurostimulation System $272 2 payments
  7. RELISTOR $266 1 payment
  8. mild Device Kit $232 1 payment
  9. Senza $180 2 payments
  10. INTELLIS $153 1 payment
  11. Other $410 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

2,483

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$90,822

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

18%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Er Diclofenac Sodium Brand 448 $33,898
Diclofenac Potassium Generic 14 $13,894
Diclofenac Sodium Generic 401 $10,325
Pregabalin Generic 261 $10,077
Gabapentin Generic 456 $6,065
Lidocaine Generic 47 $5,349
Duloxetine Hcl Generic 164 $3,886
Doxepin Hcl Generic 24 $3,134
Tizanidine Hcl Generic 187 $1,680
Celecoxib Generic 123 $1,095

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$107,977

Of which drugs: $4,590

Medicare patients

255

Average age 75

Services billed

1,996

170 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 33%
Osteoporosis 32%
Depression 29%
Ischemic heart disease 26%
Chronic kidney disease 20%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 107 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record